Skip to content
Saunatica

Peptide

KPV

  • Peptide
  • Inflammation & wound research
  • Not FDA-approved

KPV is a three-amino-acid peptide studied in cells and animals for inflammation and wound healing. No published study has administered it to people.

The basics

What is it?

KPV stands for lysine-proline-valine, the three amino acids that make up the peptide. This sequence corresponds to the end of alpha-melanocyte-stimulating hormone, or alpha-MSH. Unlike alpha-MSH, KPV does not appear to act through the usual melanocortin receptors. Cell and animal studies suggest possible effects on inflammatory signals such as NF-kB and IL-1 beta, but its actual molecular target is unknown.

Why it comes up

What are people interested in it for?

  • Wound-healing research
  • Inflammatory skin conditions
  • Gut-inflammation research
  • Corneal and skin repair
  • Inflammatory signaling

These are laboratory and animal research interests, not established benefits. FDA found no human administration, safety, or effectiveness study for KPV by any route.

Evidence

What does the research show?

Animal evidence

A 2008 study using human cell lines and mouse colitis models reported lower inflammatory markers and less tissue inflammation in groups of 10 mice. Human cell lines are laboratory evidence, not human exposure. A rabbit corneal-abrasion study reported complete surface healing in 8 of 8 KPV-treated corneas by the measured time point, compared with none in the placebo group. A mouse peritonitis study reported less inflammatory-cell accumulation. FDA found five directly relevant nonclinical KPV papers overall. A cadaver-skin study found poor passive penetration, with greater penetration after techniques that disrupted or electrically assisted the skin.

Human evidence

There are zero published human administration studies, zero randomized controlled trials, and no human cohorts, case series, case reports, pharmacokinetic studies, or clinical safety studies. Experiments involving human cells or cadaver skin do not show what happens when KPV is given to a living person.

Evidence grade

No formal GRADE assessment was found. The evidence is limited to animal and laboratory work, with no clinical evidence. Describing human certainty as very low is an editorial assessment rather than a published formal grade.

Unknowns and risks

What about safety?

FDA found no acute or repeat-dose toxicity studies, pharmacokinetic or toxicokinetic studies, genotoxicity studies, reproductive or developmental studies, or carcinogenicity studies. FAERS and FDA's food-complaint system contained no KPV cases through December 3, 2025, but incomplete reporting does not establish safety. Human risks remain unknown, including possible immune reactions, peptide aggregation, impurities, microbiological quality, and how methods that breach the skin might change absorption.

Regulatory status

Is it legal / FDA-approved?

  1. 1KPV free base and acetate are not FDA-approved, have no applicable USP/NF drug-substance monograph, and are not components of an FDA-approved drug.
  2. 2KPV's former 503A Category 2 nomination was withdrawn. It now appears in FDA's nominated-but-withdrawn table, not the current Category 2 table, and it is not Category 1.
  3. 3KPV is not on the final 503A Bulks List. Withdrawal did not authorize compounding or grant Category 1 enforcement discretion.
  4. 4On July 23, 2026, PCAC reviews KPV for wound healing and inflammatory conditions. FDA staff proposes not adding the free base or acetate form. PCAC advice is nonbinding, and FDA has not made its final decision.
  5. 5A seller's "research use only" label does not make KPV FDA-approved or authorize human use.

A practical checklist

Questions to ask a licensed provider

  • What published human evidence supports the reason I'm considering this?
  • What is known about short- and long-term human safety?
  • Is the proposed product KPV free base, KPV acetate, or something else?
  • What is its current FDA and compounding status?
  • How are identity, purity, sterility, aggregates, and microbiological quality checked?
  • Are there approved options with stronger human evidence?
  • Could the route of administration change absorption or risk?